FDA Raps ADMA Biologics for Poor Documentation, Data Controls
The FDA cited ADMA Biologics for failure to implement proper document controls and prevent unauthorized changes to data in its computer systems.
Source: Drug Industry Daily
The FDA cited ADMA Biologics for failure to implement proper document controls and prevent unauthorized changes to data in its computer systems.
Source: Drug Industry Daily